Tesamorelin is FDA-approved for exactly one use: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. No telehealth provider sells it for anti-aging or general body composition, because that use is off-label and priced as a specialty injectable.
Tesamorelin is FDA-approved for one thing: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy [1]. That is the entire approved indication. For a man without that diagnosis, every use of tesamorelin is off-label, and it is priced as a specialty injectable rather than a wellness subscription. Most men asking about it are better served by a prescribable GH-axis protocol built on sermorelin.
- Tesamorelin is approved only for HIV-associated lipodystrophy in adults [1]
- Its trials cut visceral fat about 15% and raised IGF-1 about 81% over 26 weeks [2]
- Visceral fat reaccumulated after the drug was stopped [4]
- No telehealth provider dispenses tesamorelin for anti-aging; the use is off-label
- For age-related GH decline, a monitored sermorelin protocol is the practical option
What Tesamorelin Does
Tesamorelin is a stabilized GHRH analog. It carries the full 44-amino-acid GHRH sequence with an N-terminal modification that resists enzymatic breakdown, which gives it a longer functional half-life than native GHRH. Like sermorelin, it stimulates the pituitary to release its own growth hormone rather than delivering GH directly.
The reason it reached approval is the trial data on visceral fat. In a randomized placebo-controlled trial of 412 patients over 26 weeks, visceral adipose tissue fell 15.2% with tesamorelin versus a 5.0% increase on placebo, and IGF-1 rose 81.0% versus a 5.0% decrease [2]. A pooled analysis of two phase 3 trials in 806 patients found a 15.4% treatment effect on visceral fat at 26 weeks, extending to 17.5% at 52 weeks [3]. Those numbers are real, and they were measured in a specific population.
Who Tesamorelin Is Actually For
The population in every phase 3 trial was adults with HIV-associated lipodystrophy, a condition where antiretroviral therapy drives excess visceral fat accumulation. Tesamorelin was developed and approved to manage that specific pattern of central fat [6]. Men who fit that description have a clear, on-label reason to use it under an HIV specialist.
A man without HIV-associated lipodystrophy is a different case. Using tesamorelin for general belly fat, gym recovery, or anti-aging is off-label, unstudied in that group, and dispensed at specialty-drug pricing when it is available at all. The approved indication does not stretch to cover the reasons most men search for it.
- On-label: adults with HIV-associated lipodystrophy and excess visceral fat [1]
- Off-label: general body composition, anti-aging, athletic recovery
- Not studied for age-related GH decline in men without lipodystrophy
- Priced and stocked as a specialty product, not a telehealth subscription
Why Most Men Are Better Served by Sermorelin
Access is the first reason. Telehealth platforms that offer GHRH therapy for age-related GH decline dispense compounded sermorelin, not tesamorelin. Sermorelin is a GHRH(1-29) analog that stimulates the same pituitary output through the same receptor, at a fraction of the cost, and it is prescribable through 503A or 503B compounding pharmacies.
The second reason is that the tesamorelin effect is not permanent. When the drug was stopped, visceral fat reaccumulated [4]. GHRH-analog therapy suppresses a process rather than resetting it, so both drugs require ongoing use and honest monitoring rather than a fixed course that fixes the problem for good.
Visceral fat came back after tesamorelin was stopped [4]. Any GH-axis protocol, sermorelin included, is a maintenance therapy measured against IGF-1, not a one-time reset.
Blood Sugar and Men on GH-Axis Therapy
Growth hormone opposes insulin, so glucose handling is a fair question for any man starting GH-axis therapy. The tesamorelin data is reassuring over a full course. Reviews of GHRH-analog effects describe a modest early rise in HbA1c that was no longer evident by 52 weeks, indicating neutrality with respect to glucose homeostasis over the long term [5]. The practical rule carries over to sermorelin: men with diabetes or impaired fasting glucose should have glucose monitored during the first 3 months, when any transient effect is most likely.
If You Compete in Tested Sport
GHRH analogs are banned in tested sport. Tesamorelin, sermorelin, and the GH secretagogues all appear on the 2026 WADA Prohibited List under section S2.2.4, growth hormone releasing factors [7], prohibited at all times, in and out of competition. Any man subject to anti-doping testing should treat all of them as disqualifying.
Men asking about tesamorelin usually want the body-composition benefit without the specialty-drug barrier. PeterMD prescribes compounded sermorelin with physician evaluation and follow-up labs, and runs testosterone under the same platform for men where low T is the real driver.
Bottom Line
Frequently Asked Questions
Can men take tesamorelin for belly fat?
Tesamorelin is FDA-approved only for reducing excess abdominal fat in adults with HIV-associated lipodystrophy [1]. A man without that diagnosis using it for general belly fat is using it off-label, in a population where it was not studied, at specialty-drug pricing. Telehealth platforms that offer GHRH therapy for age-related decline dispense compounded sermorelin instead.
How much visceral fat does tesamorelin remove in men?
In the phase 3 trials, tesamorelin cut visceral adipose tissue about 15%. A 412-patient study found a 15.2% reduction at 26 weeks versus a 5.0% increase on placebo, with IGF-1 rising 81.0% [2], and a pooled 806-patient analysis found a 15.4% effect at 26 weeks and 17.5% at 52 weeks [3]. Those results were measured in adults with HIV-associated lipodystrophy, not in men using it off-label.
Is tesamorelin or sermorelin better for men?
It depends on the diagnosis. For a man with HIV-associated lipodystrophy, tesamorelin is the on-label, trial-supported choice [1][2]. For a man with age-related GH decline and low or low-normal IGF-1, sermorelin is the practical option: it stimulates the same GH axis, is prescribable through compounding pharmacies, and costs far less. No head-to-head trial has compared them directly.
Does tesamorelin lower testosterone?
Tesamorelin acts on the GH axis, not the testosterone axis, so it is not a testosterone therapy in either direction. If low testosterone is a man's actual concern, GH-axis peptides will not treat it. That is a separate evaluation, and some platforms run sermorelin and testosterone therapy together under one physician.
Do the results last after stopping tesamorelin?
No. When tesamorelin was discontinued in the trials, visceral fat reaccumulated [4]. GHRH-analog therapy suppresses fat accumulation rather than permanently resetting it. Any GH-axis protocol, including sermorelin, is a maintenance therapy that requires ongoing use and monitoring against IGF-1 rather than a fixed course.
Will tesamorelin affect my blood sugar?
Growth hormone opposes insulin, so a transient effect is plausible. The tesamorelin data shows a modest early rise in HbA1c that resolved, with neutrality on glucose homeostasis by 52 weeks [5]. Men with diabetes or impaired fasting glucose starting any GHRH analog should have glucose monitored during the first 3 months.
References
- EGRIFTA SV (tesamorelin) for injection, for subcutaneous use: full prescribing information DailyMed, U.S. National Library of Medicine, 2010. Initial U.S. Approval: 2010. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- Metabolic effects of a growth hormone-releasing factor in patients with HIV New England Journal of Medicine, 2007. PMID: 18057338. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data Journal of Clinical Endocrinology & Metabolism, 2010. PMID: 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713/
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension Journal of Acquired Immune Deficiency Syndromes, 2010. PMID: 20101189. https://pubmed.ncbi.nlm.nih.gov/20101189/
- Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies Growth Hormone & IGF Research, 2015. PMID: 25555516. https://pubmed.ncbi.nlm.nih.gov/25555516/
- Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy HIV/AIDS (Auckland), 2011. PMID: 22096409. https://pubmed.ncbi.nlm.nih.gov/22096409/
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
